Trevena Announces Positive Results Of TRV027 Proof-of-Concept Study In COVID-19 Patients

(RTTNews) - Trevena Inc. (TRVN) said a study results showed that TRV027 was well-tolerated and provided initial evidence of its potential to improve biomarker and clinical endpoints associated with COVID-19 disease severity and progression.

TRV027 is a novel AT1 receptor selective agonist with the potential to treat acute lung damage/abnormal blood clotting associated with COVID-19.

The company noted that among TRV027 treated patients, 70% experienced a reduction in circulating D-dimer, compared to 27% of patients on placebo. TRV027 was associated with a 92% probability of a potential beneficial treatment effect, based on a Bayesian model analysis recommended by the study's Data Monitoring and Safety Committee (DMSC).

A post-hoc analysis indicated that patients receiving TRV027 experienced a 12 day reduction in average length of hospital stay compared to placebo, with a median reduction of 4 days.

The overall outcomes from the analysis showing a reduction of D-dimer and a reduced length of hospital stay suggest that TRV027 may effectively combat dysregulation of the renin angiotensin system caused by a COVID-19 infection and thereby improve clinical outcomes.

TRV027 is now being evaluated in two larger efficacy studies: ACTIV-4 Host Tissue led by Vanderbilt University Medical Center / NIH in the U.S., with data expected as early as mid-2022, and REMAP-CAP in the U.K.

The two global, multi-site, multi-arm COVID-19 platform trials are expected to generate extensive scientific data in up to 600 patients on the potential clinical impact of TRV027 to prevent critical illness progression, multiorgan failure, and mortality in hospitalized patients with COVID-19 infection.